TIM18 Antibody

What are the primary members of the TIM protein family and their functions in immunoregulation?

The TIM family consists of several structurally related type I membrane glycoproteins primarily expressed on T cells. The main members include:

• TIM-1: First identified as the hepatitis A virus cellular receptor (HAVCR), TIM-1 serves as a positive/negative co-stimulatory molecule for T cell proliferation and cytokine production. It binds to TIM-4 expressed on antigen-presenting cells (APCs), enhancing T helper type 2 (Th2) cell function .

• TIM-2: Functions as a receptor for Semaphorin 4A (Sema 4A), which is expressed on dendritic cells and B cells. This interaction enhances T cell activation .

• TIM-3: Acts as a negative regulator of Th1 responses, delivering inhibitory or death signals to select CD4+ T cell populations .

• TIM-4: Expressed by dendritic cells and serves as a ligand for TIM-1. Cross-linking of TIM-1 on T cells by TIM-4 enhances T cell proliferation and cytokine production .

TIM proteins are characterized by their conserved immunoglobulin and mucin domains and play critical roles in regulating T cell responses, with polymorphisms in TIM genes being associated with susceptibility to atopy and autoimmunity .

How does TIM-1 expression differ across tissues and cell types?

TIM-1 expression exhibits distinct patterns across different tissues and cell types:

• Liver: TIM-1a isoform is predominantly expressed in hepatic tissue, where it was initially identified as the hepatitis A virus cellular receptor .

• Kidney: TIM-1b isoform is primarily expressed in renal tissue. Expression is upregulated in damaged kidney tissue, suggesting a role in tissue repair and healing processes .

• Immune cells: TIM-1 is highly expressed on activated CD4+ T cells, with greater expression observed on Th2 cells compared to Th1 cells. This differential expression contributes to its role in Th2-mediated responses .

• Activated T cells: Naïve CD4+ T cells upregulate TIM-1 expression early after activation, and this expression is maintained through differentiation into both Th1 and Th2 phenotypes .

The cell and tissue-specific expression patterns of TIM-1 contribute to its diverse functions in viral entry, immune regulation, and tissue repair.

What is the significance of TIM-3 expression on tumor-infiltrating lymphocytes?

TIM-3 expression on tumor-infiltrating lymphocytes (TILs) has significant implications for cancer immunology and immunotherapy:

• Exhaustion marker: TIM-3 predominantly appears on a subset of PD-1+ T cells in tumor microenvironments, suggesting it functions as a late exhaustion marker, whereas PD-1 serves as an early exhaustion marker .

• Co-expression patterns: Flow cytometry analysis of established subcutaneous MC38 tumors in humanized TIM-3 knock-in mice showed that TIM-3 is primarily expressed on PD-1+ CD4+ and CD8+ T cells but not readily detected on PD-1-negative T cells .

• Therapy resistance: TIM-3 has been reported to be upregulated in anti-PD-1 therapy-resistant cancer patients, indicating its role in immune escape mechanisms .

• NK cell expression: While significant TIM-3 expression was not observed on tumor-infiltrating NK cells in some models, other research indicates that TIM-3 can be highly expressed on human NK cells, particularly on mature CD56dimCD16+ subsets. In vitro treatment of TIM-3+ NK cells can reverse their exhaustion phenotype .

These findings highlight TIM-3 as a critical immune checkpoint molecule in cancer and a potential target for combinatorial immunotherapy approaches.

How do anti-TIM-3 antibodies compare to other immune checkpoint inhibitors in enhancing anti-tumor responses?

Anti-TIM-3 antibodies present unique mechanisms and efficacy profiles compared to other immune checkpoint inhibitors:

• Complementary to anti-PD-1/PD-L1: While PD-1 blockade primarily enhances T-cell-related cytokines (both IFN-γ and IL-2), anti-TIM-3 antibodies like IBI104 show different effects. In mixed lymphocyte reaction (MLR) assays using dendritic cells and T cells, IBI104 did not significantly enhance IFN-γ production and only slightly increased IL-2 production, even under combinatorial conditions .

• NK cell activation: A distinctive advantage of anti-TIM-3 antibodies is their ability to alter NK cell activation status in vitro. IBI104 has been shown to greatly enhance NK cell activation and degranulation, representing a mechanistic difference from other checkpoint inhibitors .

• Combination potential: Clinical trials investigating anti-TIM-3 (LY3321367) in combination with anti-PD-L1 (LY3300054) have shown promising safety profiles. This combination approach may improve efficacy by targeting complementary immune checkpoint pathways .

• Post-PD-1 therapy response: In clinical studies, some patients who had progressed on PD-1 inhibitors showed response to TIM-3 blockade, including a confirmed partial response in a post-PD-1 small cell lung cancer patient .

These differences highlight the potential for anti-TIM-3 antibodies as complementary or alternative approaches to existing checkpoint inhibitors, particularly in cases of resistance to PD-1/PD-L1 blockade.

What are the mechanisms by which TIM-1 specific antibodies affect regulatory T cell function?

TIM-1-specific antibodies have profound and unexpected effects on regulatory T cells (Tregs):

• Deprogramming of Tregs: Agonist anti-TIM-1 monoclonal antibodies (mAbs) can effectively "deprogram" natural Tregs, rendering them unable to control T cell responses. This represents a novel mechanism by which TIM-1 ligation can modulate immune responses .

• Reciprocal effects on T cell phenotypes: Agonist TIM-1-specific antibodies exert reciprocal effects on the commitment of activated T cells to regulatory versus effector phenotypes. Specifically, these antibodies foster commitment to Th1 and Th17 phenotypes while hindering commitment to the Treg phenotype .

• Prevention of tolerance induction: Administration of agonist anti-TIM-1 mAb (like the 3B3 clone) prevents the induction of peripheral-type transplant tolerance, intensifying allograft responses by enhancing the expansion and survival of T effector cells .

• Inhibition of naive T cell conversion: TIM-1 ligation inhibits the conversion of naive CD4+ T cells into Tregs, further tilting the balance toward effector T cell responses .

These findings reveal TIM-1 as a critical regulator of the balance between effector and regulatory T cell responses, with significant implications for immune tolerance and autoimmunity.

What are the pharmacokinetic and pharmacodynamic profiles of therapeutic anti-TIM-3 antibodies in clinical trials?

Clinical trials of anti-TIM-3 antibodies have revealed important pharmacokinetic (PK) and pharmacodynamic (PD) characteristics:

These pharmacokinetic and pharmacodynamic insights are crucial for optimizing dosing regimens and predicting clinical outcomes in patients receiving anti-TIM-3 therapy.

What are the optimal assays for evaluating anti-TIM antibody efficacy in preclinical models?

Several complementary assays have proven valuable for evaluating anti-TIM antibody efficacy:

In vitro assays:

• Mixed Lymphocyte Reaction (MLR): This assay using dendritic cells and T cells evaluates cytokine production (especially IFN-γ and IL-2) in response to anti-TIM antibody treatment. While useful for PD-1 blockade assessment, it may have limitations for anti-TIM-3 antibodies as they can show minimal effects on T cell cytokine production in this context .

• NK Cell Activation Assays: Measuring NK cell activation markers and degranulation (CD107a expression) provides critical insights, particularly for anti-TIM-3 antibodies which significantly enhance NK cell function .

• T Cell Proliferation Assays: Anti-TIM-1 antibodies like RMT1-10 can inhibit antigen-specific T cell proliferation, making proliferation assays essential for characterizing their functional effects .

In vivo models:

• Humanized TIM Knock-in Mouse Models: For anti-human TIM antibodies, humanized TIM knock-in (e.g., hTIM-3-KI) mice implanted with subcutaneous tumors (e.g., MC38) allow for evaluation of tumor growth kinetics and infiltrating lymphocyte analysis .

• Allograft Rejection Models: These models are particularly useful for anti-TIM-1 antibodies, which can prevent transplant tolerance .

• Autoimmune Disease Models: Anti-TIM-1 antibodies like RMT1-10 reduce the severity of experimental autoimmune encephalomyelitis, making these models valuable for assessing immunomodulatory functions .

Flow cytometry analysis of tumor-infiltrating lymphocytes for TIM expression, exhaustion markers, and functional outputs provides essential mechanistic insights complementing efficacy endpoints.

What techniques are most effective for detecting TIM expression in different tissue samples?

Multiple techniques can be employed for detecting TIM protein expression, each with specific advantages:

Immunohistochemistry (IHC):

• Offers visualization of TIM expression in tissue context

• Example application: TIM-2 was detected in mouse liver sinusoids using anti-mouse TIM-2 antigen affinity-purified polyclonal antibody at 1.7 μg/mL, visualized with DAB (brown) and counterstained with hematoxylin .

• Best for fixed tissues and spatial distribution analysis

Flow Cytometry:

• Enables quantitative assessment and co-expression analysis

• Particularly useful for analyzing TIM expression on specific immune cell subsets

• Successfully used to demonstrate TIM-3 expression predominantly on PD-1+ T cells in tumor microenvironments

• Optimal for single-cell suspensions from blood or dissociated tissues

Western Blotting:

• Provides information about protein size and possible post-translational modifications

• Useful for semi-quantitative analysis of protein levels

• Can detect specific TIM isoforms based on molecular weight

• Most suitable for cultured cells or homogenized tissues

ELISA:

• Allows quantitative measurement of soluble TIM forms

• Useful for serum/plasma samples and supernatants

• Can be applied to detect TIM-specific antibodies as demonstrated with mouse TIM-2 antibody evaluations

For tissue-specific expression patterns, combining techniques provides comprehensive insights. For example, TIM-1 exists in two splice variants: TIM-1a (predominantly in liver) and TIM-1b (predominantly in kidney), which can be distinguished using isoform-specific antibodies and appropriate detection methods .

How can researchers optimize combinatorial therapies using anti-TIM antibodies with other immune checkpoint inhibitors?

Optimizing combinatorial therapies with anti-TIM antibodies requires systematic approaches:

Staggered vs. Concurrent Administration:

• Clinical trials have evaluated concurrent administration of anti-TIM-3 (LY3321367) with anti-PD-L1 (LY3300054) at doses ranging from 70mg-1200mg and 200mg-700mg respectively

• Researchers should consider whether sequential administration might provide superior outcomes based on tumor microenvironment dynamics

Dose Optimization:

• Target engagement analysis indicates 600mg Q2W of anti-TIM-3 maintained steady-state target engagement

• Dose-finding studies should evaluate whether lower doses of combined checkpoint inhibitors can achieve similar efficacy with reduced toxicity

Patient Selection Strategies:

• TIM-3 upregulation in anti-PD-1 therapy-resistant patients suggests prioritizing this population for combination trials

• Biomarker development focusing on TIM expression patterns on tumor-infiltrating lymphocytes may identify optimal responders

Monitoring Immune Cell Subsets:

• Since anti-TIM-3 antibodies particularly enhance NK cell activation while anti-PD-1 primarily affects T cells, comprehensive immune monitoring should include:

  • NK cell activation status and frequency

  • T cell subset analysis (effector vs. regulatory)

  • Cytokine profiling focused on both T cell (IFN-γ, IL-2) and NK cell-associated cytokines

Managing Immune-Related Adverse Events:

• Clinical data indicates mild adverse events (Grade ≤2) with anti-TIM-3 monotherapy and combination therapy, with only one patient experiencing Grade 3 anemia in combination treatment

• Developing standardized management protocols for potential synergistic toxicities is essential

Early-phase trials demonstrate that anti-TIM-3 combinations are well-tolerated, providing a foundation for expanded efficacy studies in specific cancer populations.

Why might there be discrepancies between in vitro and in vivo efficacy of anti-TIM antibodies?

Researchers have observed important discrepancies between in vitro and in vivo efficacy of anti-TIM antibodies that warrant careful consideration:

Documented Discrepancies:

• The anti-TIM-3 antibody IBI104 demonstrated limited enhancement of T cell cytokine production (IFN-γ and IL-2) in mixed lymphocyte reaction assays in vitro, despite showing significant anti-tumor activity in vivo .

• While IBI104 significantly altered NK cell activation status in vitro, different immune cell populations may dominate the response in vivo depending on the model used .

Potential Explanations:

• Complex Tumor Microenvironment Factors:

  • The tumor microenvironment contains multiple cell types and immunosuppressive factors absent in simplified in vitro systems

  • Hypoxia, nutrient competition, and tumor-derived factors can significantly alter antibody efficacy

• Differential Target Expression:

  • TIM expression patterns can differ between cultured cells and tumor-infiltrating lymphocytes

  • For example, TIM-3 and PD-1 can be significantly induced on NK cells with MHC-I knockout tumor cells in vivo but may not show similar expression in vitro

• Antibody Biodistribution and Pharmacokinetics:

  • In vivo, antibody concentration at target sites is affected by biodistribution, clearance, and tumor penetration

  • These pharmacokinetic factors cannot be adequately modeled in vitro

• Host Compensatory Mechanisms:

  • Immune system adaption and compensatory pathways activated in vivo may be absent in vitro

  • The broader immune milieu creates feedback mechanisms impossible to fully recapitulate in culture

To address these discrepancies, researchers should employ complementary models, including ex vivo analysis of tumor-infiltrating lymphocytes, and correlate in vitro findings with multiple in vivo endpoints.

How can researchers address anti-drug antibody development when using anti-TIM antibodies in preclinical and clinical studies?

Anti-drug antibody (ADA) development represents a significant challenge in both preclinical and clinical development of anti-TIM antibodies:

Prevalence and Impact:

• In clinical trials with anti-TIM-3 antibody LY3321367, 68.2% of patients receiving monotherapy and 88.2% receiving combination therapy developed treatment-emergent ADAs .

• Despite high ADA prevalence, most patients had low ADA titers without significant impact on pharmacokinetics .

Management Strategies:

• Antibody Engineering Approaches:

  • Humanization or use of fully human antibodies reduces immunogenicity

  • Framework modifications to eliminate T-cell epitopes

  • Use of computational tools to predict and eliminate immunogenic sequences

• Administration Protocols:

  • Optimizing dosing schedules to maintain target coverage despite potential ADA interference

  • For example, 600 mg Q2W dosing of LY3321367 maintained target engagement at steady-state despite ADA development

  • Consider co-administration of immunomodulatory agents that may reduce ADA formation

• Monitoring and Assessment:

  • Implement regular ADA monitoring using validated assays

  • Correlate ADA titers with pharmacokinetic parameters and clinical responses

  • Distinguish neutralizing from non-neutralizing ADAs

• Clinical Management of ADA-Related Events:

  • Develop protocols for managing infusion-related reactions, which occurred in one patient with high ADA titers in the LY3321367 trial

  • Consider premedication regimens for patients with confirmed ADAs

• Translational Considerations:

  • Use species-matched antibodies in preclinical models to better predict clinical immunogenicity

  • Employ humanized mouse models where appropriate

Careful monitoring of ADA development should be incorporated into study designs to distinguish true treatment failures from antibody neutralization effects.

What control antibodies are most appropriate for different experimental applications involving TIM proteins?

Selecting appropriate control antibodies is critical for rigorous experimental design when studying TIM proteins:

For Flow Cytometry and Immunohistochemistry:

• Isotype Controls:

  • Match the isotype, species, and subclass of the experimental antibody

  • For rabbit anti-TIM-1 polyclonal antibodies, use rabbit polyclonal IgG

  • For rat anti-mouse TIM-1 monoclonal antibody (clone RMT1-10), use rat IgG2a isotype control

  • Apply at identical concentrations to experimental antibodies

• Blocking Controls:

  • Pre-incubation with recombinant TIM protein to demonstrate specificity

  • Important for polyclonal antibodies which may have broader epitope recognition

For Functional Assays:

• Antagonist vs. Agonist Control Comparison:

  • Different anti-TIM-1 antibodies can have opposing functions:

    • RMT1-10 inhibits antigen-specific T cell proliferation

    • Other TIM-1 antibodies have agonistic functions

  • Including both types provides mechanistic insights

• Cross-Reactivity Controls:

  • Test antibody specificity against related TIM family members

  • For example, mouse TIM-2 antibody showed less than 2% cross-reactivity with recombinant human TIM-1

• Functional Blocking Controls:

  • F(ab')2 fragments to distinguish Fc-dependent from Fc-independent effects

  • Particularly important when studying NK cells which express Fc receptors

For In Vivo Studies:

• Matched Non-targeting Antibodies:

  • Species and isotype-matched antibodies against irrelevant antigens

  • Should have similar half-life and biodistribution properties

• Dose Titration Controls:

  • Include multiple dose levels to establish dose-response relationships

  • Trials with LY3321367 used doses ranging from 3mg-1200mg, showing dose-dependent target engagement

Properly controlled experiments are essential for distinguishing true biological effects from experimental artifacts and for establishing mechanism of action.

What are the emerging applications of anti-TIM antibodies in cancer immunotherapy?

Recent research reveals several promising applications for anti-TIM antibodies in cancer immunotherapy:

Overcoming Resistance to Existing Checkpoint Inhibitors:

• TIM-3 is upregulated in anti-PD-1 therapy-resistant cancer patients, suggesting anti-TIM-3 antibodies as a strategy to address resistance mechanisms .

• Clinical evidence supports this approach, with a post-PD-1 small cell lung cancer (SCLC) patient showing >20% tumor regression later confirmed as a partial response when treated with the anti-TIM-3 antibody LY3321367 .

Novel Combination Approaches:

• The combination of anti-TIM-3 (LY3321367) with anti-PD-L1 (LY3300054) demonstrated good tolerability in phase 1a/1b trials, with mostly mild (Grade ≤2) treatment-related adverse events .

• This combination approach targets complementary immune pathways, potentially enhancing efficacy beyond single-agent checkpoint blockade.

Receptor Internalization Mechanisms:

• Novel antibodies like IBI104 are designed to trigger TIM-3 receptor internalization, representing a mechanistically distinct approach to simply blocking receptor-ligand interactions .

• This internalization strategy may provide more durable receptor inhibition compared to competitive antagonism.

NK Cell-Focused Applications:

• Anti-TIM-3 antibodies like IBI104 can significantly enhance NK cell activation and degranulation in vitro, suggesting particular value in NK cell-rich tumors .

• This represents a distinct mechanism from many other checkpoint inhibitors that primarily target T cell responses.

These emerging applications highlight the potential of anti-TIM antibodies to address unmet needs in cancer immunotherapy, particularly for patients who fail to respond to or develop resistance to current standard checkpoint inhibitors.

How do TIM antibodies affect the balance between different T helper cell subsets in autoimmune and inflammatory conditions?

TIM antibodies exert complex effects on T helper cell subset balance with significant implications for autoimmune and inflammatory diseases:

Effects on Th1/Th2 Balance:

Impact on Th17 Development:

• Agonist TIM-1-specific antibodies foster commitment to the Th17 phenotype while simultaneously hindering regulatory T cell differentiation .

• This Th17-promoting effect has significant implications for autoimmune conditions where Th17 cells play pathogenic roles.

• In experimental autoimmune encephalomyelitis (EAE), anti-TIM-1 antibody (clone RMT1-10) reduces disease severity and delays onset, likely by modulating the balance between pathogenic and regulatory T cell subsets .

Treg/Th17 Axis Modulation:

• TIM-1 ligation by agonistic antibodies can effectively "deprogram" natural Tregs, rendering them unable to control T cell responses .

• This deprogramming effect, combined with inhibition of naive CD4+ T cell conversion into Tregs, significantly alters the Treg/Th17 balance .

• In transplantation models, anti-TIM-1 mAb (3B3) prevents the induction of peripheral-type transplant tolerance by enhancing effector T cell expansion and survival while inhibiting regulatory mechanisms .

These findings reveal TIM antibodies as powerful modulators of T helper cell differentiation and function, with potential applications in treating autoimmune disorders, transplant rejection, and inflammatory conditions.

What is the role of TIM proteins in viral infections and how might anti-TIM antibodies be utilized in infectious disease research?

TIM proteins serve crucial functions in viral infections, offering potential targets for therapeutic intervention:

Viral Entry and Receptor Functions:

• TIM-1 was first identified as the hepatitis A virus cellular receptor (HAVCR), making it a critical factor in hepatitis A virus entry into cells .

• Beyond hepatitis A, TIM-1 acts as a receptor for multiple viruses, including Dengue, Ebola, and Marburg viruses .

• These findings highlight TIM-1 as a potential broad-spectrum target for antiviral interventions.

Tissue-Specific Expression and Viral Tropism:

• TIM-1 exists in two main splice variants with differential tissue expression:

  • TIM-1a is predominantly expressed in the liver, correlating with hepatotropic viral infections .

  • TIM-1b is expressed primarily in kidney tissue .

• This tissue-specific expression pattern contributes to viral tropism and disease manifestations.

Immune Regulation During Viral Infection:

• TIM proteins modulate immune responses during viral infections:

  • TIM-1 acts as a co-stimulatory molecule for T cell proliferation and cytokine production .

  • TIM-3 functions as a negative regulator of Th1 responses, potentially limiting antiviral immunity in some contexts .

Potential Applications of Anti-TIM Antibodies:

• Blocking Viral Entry:

  • Anti-TIM-1 antibodies could potentially block viral entry for TIM-1-utilizing viruses like hepatitis A, Ebola, and Marburg

  • This approach might provide broad-spectrum antiviral protection against emerging viruses that use TIM-1 as an entry receptor

• Enhancing Antiviral Immunity:

  • Anti-TIM-3 antibodies might enhance virus-specific T cell responses by preventing T cell exhaustion during chronic viral infections

  • This approach could be particularly valuable for persistent viral infections where T cell exhaustion limits viral clearance

• Research Tools:

  • Anti-TIM antibodies serve as valuable tools for studying viral entry mechanisms and immune regulation during infection

  • They allow researchers to distinguish between viral binding and entry steps in the infection process

These findings highlight the potential for anti-TIM antibodies in both basic research on viral pathogenesis and development of novel antiviral strategies.

What are the key binding characteristics of commercially available anti-TIM antibodies?

Table 1: Binding Characteristics of Selected Anti-TIM Antibodies

Commercial antibodies against TIM family members demonstrate diverse characteristics suitable for various research applications. Importantly, researchers should note that cross-reactivity between TIM family members is generally minimal, as exemplified by the mouse TIM-2 antibody showing less than 2% cross-reactivity with human TIM-1 . Validated applications range from basic detection methods (ELISA, Western blot, IHC) to functional assays and clinical applications.

How does the efficacy of anti-TIM-3 antibody monotherapy compare with combination therapy in clinical studies?

Table 2: Clinical Outcomes of Anti-TIM-3 Antibody Therapy Approaches

While complete efficacy data from the clinical trials is limited in the available search results, early phase 1a/1b findings demonstrate that both monotherapy and combination approaches with anti-TIM-3 antibodies have manageable safety profiles. The observation of tumor regression in post-PD-1 therapy patients suggests potential utility in overcoming resistance to existing checkpoint inhibitors. The high rate of anti-drug antibody development in both treatment arms warrants attention, though it generally did not impact pharmacokinetics or treatment outcomes .

What are the expression patterns of TIM proteins in different tumor types and their correlation with clinical outcomes?

Table 3: TIM Expression in Tumor Microenvironments and Clinical Correlations

The expression patterns of TIM proteins, particularly TIM-3, in the tumor microenvironment provide valuable insights for cancer immunotherapy. TIM-3 appears to be predominantly expressed on PD-1+ T cells, supporting its role as a late exhaustion marker compared to PD-1, which functions as an early exhaustion marker . The upregulation of TIM-3 in anti-PD-1 therapy-resistant patients suggests its involvement in resistance mechanisms and highlights the potential value of anti-TIM-3 therapies for patients who progress on PD-1/PD-L1 inhibitors .

The presence of TIM-3 on NK cells, particularly mature CD56dimCD16+ subsets, indicates potential functional relevance beyond T cell regulation, which may contribute to the efficacy of anti-TIM-3 antibodies through NK cell-mediated mechanisms .

What are the recommended protocols for studying TIM protein internalization and its functional consequences?

Studying TIM protein internalization requires specialized techniques to capture this dynamic process:

Flow Cytometry-Based Internalization Assays:

• Treat cells expressing TIM proteins with fluorescently-labeled anti-TIM antibodies at 4°C (prevents internalization)

• Shift to 37°C to allow internalization for various time points (5-60 minutes)

• Acid wash or trypsin treatment to remove surface-bound antibodies

• Remaining fluorescence indicates internalized antibody-receptor complexes

• IBI104, a novel anti-TIM-3 antibody, has been shown to induce receptor internalization, making this a critical assay for characterizing its mechanism of action

Confocal Microscopy for Visualization:

• Fluorescently label anti-TIM antibodies

• Perform pulse-chase experiments with fixation at different time points

• Co-stain with markers for early endosomes (EEA1), late endosomes/lysosomes (LAMP1/2)

• This approach visualizes trafficking of internalized TIM proteins through the endosomal-lysosomal pathway

Functional Consequence Assessment:

• Compare effects of internalizing versus non-internalizing anti-TIM antibodies

• Measure downstream signaling (phospho-flow cytometry for relevant pathways)

• Assess functional outcomes like cytokine production, proliferation, or cytotoxicity

• For TIM-3, evaluate effects on both T cell and NK cell functions, as IBI104-induced internalization enhances NK cell activation and degranulation

Receptor Recycling vs. Degradation:

• Cycloheximide chase experiments to block new protein synthesis

• Western blot analysis of total TIM protein levels over time

• Surface biotinylation pulse-chase to track fate of surface receptors

These methodologies provide complementary insights into the mechanisms and functional consequences of TIM protein internalization, which may be particularly relevant for therapeutic antibodies designed to modulate TIM signaling.

How should researchers design experiments to evaluate the impact of TIM antibodies on immune cell exhaustion?

Designing experiments to evaluate TIM antibodies' impact on immune cell exhaustion requires comprehensive approaches:

In Vitro Exhaustion Models:

• Chronic Stimulation Model:

  • Repeatedly stimulate T cells or NK cells with antigens or activating ligands

  • Monitor progressive upregulation of exhaustion markers (PD-1, TIM-3, LAG-3)

  • Add anti-TIM antibodies at different timepoints to assess prevention vs. reversal of exhaustion

  • Flow cytometry analysis showed TIM-3 is predominantly expressed on PD-1+ T cells, suggesting it represents a late exhaustion marker compared to PD-1

• Tumor-Conditioned Media Approach:

  • Culture immune cells in tumor-conditioned media to induce exhaustion

  • Treatment with anti-TIM antibodies to evaluate functional recovery

  • Assess cytokine production, proliferation, and cytotoxic potential

Ex Vivo Analysis:

• Patient-Derived TIL Analysis:

  • Isolate tumor-infiltrating lymphocytes from patient samples

  • Characterize baseline exhaustion phenotype (TIM-3/PD-1 co-expression)

  • Ex vivo treatment with anti-TIM antibodies alone or in combination with other checkpoint inhibitors

  • Functional recovery assessment through cytokine production and proliferation assays

• Paired Blood-Tumor Analysis:

  • Compare exhaustion profiles between circulating and tumor-infiltrating immune cells

  • Evaluate differential responses to anti-TIM treatment based on tissue origin and exhaustion state

In Vivo Models:

• Humanized TIM Knock-in Models:

  • Use humanized TIM-3 knock-in (hTIM-3-KI) mice implanted with tumors like MC38

  • Treatment with anti-TIM antibodies at various timepoints during tumor progression

  • Flow cytometric analysis of TIM-3/PD-1 co-expression patterns on tumor-infiltrating T cells and NK cells

  • Correlation of expression patterns with functional status and response to therapy

• Sequential vs. Combination Treatment:

  • Compare sequential vs. concurrent administration of anti-TIM and anti-PD-1 antibodies

  • Evaluate whether targeting the early exhaustion marker (PD-1) before the late marker (TIM-3) improves outcomes

Key Analytical Endpoints:

• Multi-parameter flow cytometry to assess multiple exhaustion markers simultaneously

• Transcriptional profiling to evaluate exhaustion-associated gene signatures

• Functional assays (cytokine production, proliferation, cytotoxicity)

• In vivo tumor growth kinetics and survival analysis

These experimental designs capture the complexity of immune cell exhaustion and provide comprehensive assessment of anti-TIM antibodies' impact on restoring immune function.

What techniques are most appropriate for evaluating anti-TIM antibody-mediated effects on the tumor microenvironment?

Comprehensive evaluation of anti-TIM antibody effects on the tumor microenvironment requires multi-modal approaches:

Spatial Profiling Techniques:

• Multiplex Immunohistochemistry/Immunofluorescence:

  • Simultaneously visualize multiple markers (TIM proteins, immune cell subsets, functional markers)

  • Quantify spatial relationships between different cell populations

  • Assess changes in immune infiltration patterns following anti-TIM antibody treatment

  • Example application: Visualizing TIM-2 expression in mouse liver sinusoids using anti-mouse TIM-2 antibody

• Spatial Transcriptomics:

  • Map gene expression changes across the tumor microenvironment

  • Identify regional variations in response to anti-TIM antibodies

  • Correlate with protein expression data from IHC

Functional Assessment:

• Ex Vivo Tumor Slice Cultures:

  • Maintain intact tumor architecture in culture

  • Treat with anti-TIM antibodies and assess immune cell mobilization and function

  • Measure cytokine production in the preserved microenvironment

• Flow Cytometry-Based Approaches:

  • Comprehensive immune profiling of dissociated tumors

  • Analysis of TIM expression on different immune cell subsets

  • Proven effective for demonstrating TIM-3 expression predominantly on PD-1+ T cells in tumor microenvironments

  • Intracellular cytokine staining to assess functional state

In Vivo Imaging:

• Intravital Microscopy:

  • Visualize immune cell dynamics in live tumor-bearing animals

  • Track immune cell infiltration and behavior following anti-TIM antibody treatment

  • Requires fluorescently labeled antibodies or reporter mice

• PET Imaging with Radiolabeled Antibodies:

  • Assess tumor penetration and biodistribution of anti-TIM antibodies

  • Monitor changes in metabolic activity following treatment

Secretome Analysis:

• Multiplex Cytokine Profiling:

  • Measure changes in cytokine/chemokine profiles within the tumor microenvironment

  • Correlate with immune cell phenotypes and functional states

  • Particularly valuable for assessing NK cell activation following anti-TIM-3 antibody treatment

• Single-Cell Secretome Analysis:

  • Identify which cell populations respond to anti-TIM antibody treatment

  • Characterize heterogeneity in response patterns

These complementary approaches provide a comprehensive view of how anti-TIM antibodies reshape the tumor microenvironment, affecting both spatial organization and functional properties of tumor-infiltrating immune cells.

What are the most promising new approaches for developing next-generation anti-TIM antibodies with enhanced efficacy?

Several innovative approaches show promise for developing next-generation anti-TIM antibodies:

Novel Antibody Designs:

• Internalizing Antibodies:

  • Antibodies specifically designed to trigger receptor internalization, like IBI104 for TIM-3

  • This approach may provide more durable inhibition than simple receptor blocking

  • Potential for targeted delivery of toxins or immunostimulatory molecules to TIM-expressing cells

• Bispecific Antibodies:

  • Targeting TIM proteins and complementary immune checkpoints simultaneously

  • Potential configurations include TIM-3/PD-1 or TIM-1/TIM-4 bispecifics

  • May address heterogeneity in checkpoint expression and resistance mechanisms

• Fc-Engineered Variants:

  • Enhanced antibody-dependent cellular cytotoxicity (ADCC) for selective depletion of exhausted TIM+ cells

  • Fc-silent variants when ADCC is undesirable

  • Particularly relevant given the high TIM-3 expression on mature NK cells

Targeting Novel Epitopes:

• Structure-Guided Design:

  • Computational approaches to identify novel binding epitopes

  • Development of antibodies that disrupt specific protein-protein interactions

  • Similar to approaches used in the AbDesign algorithm for antibody design

• Allosteric Modulators:

  • Antibodies targeting non-ligand binding regions to modulate receptor function

  • May offer more selective modulation of signaling pathways

Combination Strategies:

• Rational Sequencing:

  • Sequential administration of anti-TIM and other checkpoint inhibitors based on expression kinetics

  • Targeting early exhaustion markers (PD-1) before late markers (TIM-3)

• Microenvironment Modifiers:

  • Combining anti-TIM antibodies with agents targeting immunosuppressive components of the tumor microenvironment

  • May enhance infiltration and function of anti-TIM-responsive immune cells

These approaches represent promising directions for enhancing the efficacy of anti-TIM antibodies beyond current generation therapeutics, with potential applications in cancer immunotherapy, autoimmune diseases, and viral infections.

What are the current gaps in understanding TIM protein biology that future research should address?

Several critical knowledge gaps in TIM protein biology warrant focused investigation:

Structural and Functional Relationships:

• Complete structural characterization of TIM family members in complex with their respective ligands

• Identification of structure-function relationships that could guide more selective therapeutic targeting

• Understanding how polymorphisms in TIM genes mechanistically influence disease susceptibility

Signaling Pathways:

• Comprehensive mapping of downstream signaling pathways activated by different TIM proteins

• Elucidation of how TIM-3 signaling contributes to T cell exhaustion at the molecular level

• Understanding the apparently contradictory functions of TIM-1 as both a co-stimulatory and co-inhibitory molecule depending on context

Cell Type-Specific Functions:

• Deeper investigation of TIM-3 function on NK cells, given its high expression on mature CD56dimCD16+ NK cell subsets

• Characterization of TIM expression and function on non-lymphoid cells

• Understanding tissue-specific roles of TIM proteins beyond immune regulation

Regulatory Mechanisms:

• Factors controlling TIM expression in different contexts (infection, cancer, autoimmunity)

• Mechanisms behind TIM-3 upregulation in anti-PD-1 therapy-resistant cancer patients

• Understanding how TIM-1 ligation leads to "deprogramming" of regulatory T cells at the molecular level

Cross-Talk with Other Pathways:

• Interactions between TIM signaling and other immune checkpoint pathways

• Integration of TIM signals with antigen receptor signaling in different immune cell types

• Role of TIM proteins in modulating cytokine receptor signaling networks

Therapeutic Resistance:

• Mechanisms of resistance to anti-TIM antibody therapies

• Predictive biomarkers for response to anti-TIM antibody treatment

• Strategies to overcome or prevent resistance

Addressing these knowledge gaps would significantly advance our understanding of TIM protein biology and inform the development of more effective therapeutic strategies targeting these important immunoregulatory molecules.

How might emerging technologies enhance the development and application of TIM-targeted therapies?

Emerging technologies offer promising approaches to advance TIM-targeted therapies:

Advanced Antibody Engineering:

• Computational Design:

  • Algorithms like AbDesign that use information on backbone conformations and sequence-conservation patterns to design new antibodies

  • Structure-based design of antibodies with optimized binding properties and reduced immunogenicity

  • In silico prediction of epitopes that induce receptor internalization, as observed with the TIM-3 antibody IBI104

• High-throughput Screening:

  • Single B-cell screening technologies to identify naturally occurring high-affinity anti-TIM antibodies

  • Yeast or phage display libraries to discover novel binding modalities

Precision Medicine Approaches:

• Biomarker Development:

  • Single-cell multi-omics to identify patient-specific TIM expression patterns

  • Liquid biopsy approaches to monitor TIM expression dynamically during treatment

  • Predictive biomarkers for response to anti-TIM therapy (e.g., patterns of TIM-3/PD-1 co-expression on TILs)

• Patient-Derived Models:

  • Organoid cultures incorporating immune components to test anti-TIM therapies on patient-specific samples

  • Humanized mouse models for personalized immunotherapy testing

Novel Delivery Platforms:

• Gene Editing:

  • CRISPR/Cas9-based approaches to modify TIM expression or signaling

  • CAR-T cells engineered to overcome TIM-mediated immunosuppression

• Nanomedicine:

  • Nanoparticle-based delivery of anti-TIM antibodies or siRNA targeting TIM proteins

  • Enhanced tumor penetration and sustained local delivery

Advanced Imaging:

• Multiplexed Imaging:

  • Imaging mass cytometry or multiplexed ion beam imaging (MIBI) to characterize the spatial context of TIM expression

  • Correlation with treatment response and resistance patterns

• Molecular Imaging:

  • PET tracers targeting TIM proteins for non-invasive monitoring of expression

  • Assessment of antibody biodistribution and target engagement in vivo

Artificial Intelligence:

• Predictive Modeling:

  • Machine learning algorithms to predict optimal anti-TIM combination therapies

  • Analysis of large-scale patient data to identify response patterns

• Image Analysis:

  • Automated quantification of TIM expression in tissue samples

  • Pattern recognition in multiplexed imaging data to identify predictive features

These technological advances promise to accelerate the development of more effective TIM-targeted therapies and enable more precise application in personalized medicine approaches.